A recent international study has found that a single dose of a new RSV vaccine, called RSVPreF3 OA, can protect adults aged 60 and older from serious lung infections caused by the respiratory syncytial virus (RSV) for up to three seasons. The study involved over 24,000 older adults across 17 countries and tested how well
Donating blood may do more than just help others—it could also enhance the health of your own blood cells. A recent study suggests that frequent blood donation may encourage the growth of beneficial blood cell mutations, potentially lowering the risk of blood-related diseases. Researchers at the Francis Crick Institute in London analyzed blood samples from
A recent study by Uppsala University and Chalmers University of Technology has found that coffee from many workplace coffee machines contains high levels of cholesterol-raising compounds. The research, published in Nutrition, Metabolism & Cardiovascular Diseases, highlights the difference between coffee brewed in these machines and coffee made using regular paper filter drip coffee makers.
Novo Nordisk is exploring a higher-dose version of semaglutide to enhance weight loss treatments. In a recent phase 3b clinical trial called STEP UP, a 7.2-mg weekly dose of semaglutide helped participants lose an average of 20.7% of their body weight over 72 weeks. This significantly outperformed the 2.4-mg dose marketed as Wegovy, which led
Arrowhead Pharmaceuticals announced positive results from its Phase 3 PALISADE study on plozasiran, a new drug for treating familial chylomicronemia syndrome (FCS). FCS is a rare genetic condition that causes extremely high triglyceride levels, leading to serious health issues like acute pancreatitis. Currently, there are no approved treatments for FCS in the United States or
Merck & Co.’s new vaccine, CAPVAXIVE (V116), has been approved by the FDA for preventing invasive diseases and pneumonia in adults 18 and older caused by specific strains of the bacteria Streptococcus pneumoniae. This vaccine is particularly aimed at protecting adults over 50 from around 84% of invasive pneumococcal diseases. In several studies, CAPVAXIVE showed
Today the Team at JoinAStudy.ca would like to acknowledge the dedicated work of one of our Investigators, Dr. Sabeen Anwar. Dr. Anwar and her team have played a key part in gathering new data to advance the knowledge of patient care for the condition of Psoriatic Arthritis. The APPRAISE study, a prospective observational investigation conducted
Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116, to rival Pfizer’s current market dominance in vaccines of this nature. In the United States, Prevnar 20 (Pfizer’s vaccine) currently commands a dominant 95% share. However, Merck contends that V116 offers broader protection, making it
Regeneron Pharmaceuticals and Sanofi have announced positive results from their phase 3 trial, titled NOTUS, evaluating Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD). The trial demonstrated that Dupixent significantly reduced COPD exacerbations by 34% (compared to placebo) in patients with moderate-to-severe COPD who also show evidence of type 2 inflammation of
Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,
